{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:47:14Z","timestamp":1793886434719,"version":"4.8.0"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M743016"],"award-info":[{"award-number":["2023M743016"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LY20H160028"],"award-info":[{"award-number":["LY20H160028"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cervical cancer poses a significant global threat to women\u2019s health. However, current therapeutic interventions, such as radiotherapy, chemotherapy, surgical resection, and immune checkpoint inhibitors, face limitations in the advanced stages of the disease. Given the immunosuppressive microenvironment in cervical cancer, it is imperative to explore novel perspectives. In this regard, STING agonists have emerged as promising candidates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The expression profiles and clinicopathological data were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets. Prognostic analysis of STING downstream genes (CCL5, CXCL9, CXCL10) and immune infiltration analysis were conducted using Kaplan-Meier Plotter, ESTIMATE, and\n                      <jats:italic>deconvo_CIBERSOR<\/jats:italic>\n                      . Single-cell RNA-seq (scRNA-seq) analysis was conducted to evaluate the potential of MSA-2 in cervical cancer treatment employing SingleR, chi-squared test, and Gene Set Enrichment Analysis (GSEA). Cellular interaction analysis utilized the CellChat package to assess the potentiation of cellular interaction following MSA-2 administration. Murine tumor models involving U14 and TC-1, were conducted, and the IF of tissue was subsequently conducted to assess the tumor microenvironment status after treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Prognosis in cervical cancer correlated with elevated expression of STING downstream genes, indicating prolonged survival and reduced recurrence. These genes positively correlated with immune infiltration, influencing stromal scores, immune scores, and estimate scores. Specific immune cell populations, including CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells, M1-type macrophages, NK cells, and T follicular helper cells, were associated with STING downstream genes. scRNA-seq in a classic immune-excluded model revealed that MSA-2 exerts priming and activating functions on vital components within TME, and intensifies their intercellular communications. The\n                      <jats:italic>in vivo<\/jats:italic>\n                      assay ultimately demonstrated that MSA-2, either as a standalone treatment or in combination with anti-PD-1, effectively suppressed the growth of subcutaneous cervical tumors. Moreover, the combination strategy significantly augmented efficacy compared to anti-PD-1 monotherapy by eliciting a robust antitumor immune response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study highlights the pivotal role of the STING pathway and the potential of MSA-2 in reshaping the immune microenvironment in cervical cancer. Combining MSA-2 with immune checkpoint inhibitors presents a transformative approach, holding promise for improved prognosis. Further investigations are warranted to explore the broader immune landscape and potential long-term effects of MSA-2 in cervical cancer treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2024.1342647","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:26:32Z","timestamp":1710375992000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":43,"title":["STING agonist inflames the cervical cancer immune microenvironment and overcomes anti-PD-1 therapy resistance"],"prefix":"10.3389","volume":"15","author":[{"given":"Tianye","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengke","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuze","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/ijgo.13865","article-title":"Cancer of the cervix uteri: 2021 update","author":"Bhatla","year":"2021","journal-title":"Int J Gynaecol Obstet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2020.10.034","article-title":"HPV post-infection microenvironment and cervical cancer","volume":"497","author":"Yuan","year":"2021","journal-title":"Cancer Lett"},{"key":"B4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.critrevonc.2019.02.009","article-title":"Systemic therapy in cervical cancer: 30 years in review","volume":"137","author":"Liontos","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2021-003001","article-title":"Global challenges of radiotherapy for the treatment of locally advanced cervical cancer","volume":"32","author":"Mayadev","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3390\/microorganisms7070199","article-title":"The host-microbe interplay in human papillomavirus-induced carcinogenesis","volume":"7","author":"Wakabayashi","year":"2019","journal-title":"Microorganisms"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-14-1099","article-title":"New strategies in advanced cervical cancer: from angiogenesis blockade to immunotherapy","volume":"20","author":"Tewari","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102385","article-title":"Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials","volume":"106","author":"Monk","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1201675","article-title":"The abscopal effect of immune-radiation therapy in recurrent and metastatic cervical cancer: a narrative review","volume":"14","author":"Ollivier","year":"2023","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40364-020-00212-5","article-title":"Resistance to PD-1\/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives","volume":"8","author":"Sun","year":"2020","journal-title":"biomark Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1084887","article-title":"Towards a consensus definition of immune exclusion in cancer","volume":"14","author":"Tiwari","year":"2023","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1038\/s41467-018-04724-5","article-title":"Spatial maps of prostate cancer transcriptomes reveal an unexplored landscape of heterogeneity","volume":"9","author":"Berglund","year":"2018","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.01.015","article-title":"Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer","volume":"530","author":"Kang","year":"2022","journal-title":"Cancer Lett"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.08.018","article-title":"Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and\/or metastatic cervical cancer","volume":"163","author":"O'Malley","year":"2021","journal-title":"Gynecol Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.12.034","article-title":"Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528\/NRG-GY002)","volume":"157","author":"Santin","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.08.026","article-title":"PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer","volume":"159","author":"Rischin","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-22-1280","article-title":"Efficacy and safety of the anti-PD-L1 mAb socazolimab for recurrent or metastatic cervical cancer: a phase I dose-escalation and expansion study","volume":"28","author":"An","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1142256","article-title":"Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1-positive advanced cervical cancer: a phase II, single-arm study","volume":"14","author":"An","year":"2023","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13045-023-01445-1","article-title":"First-in-human phase I\/Ib study of QL1706 (PSB205), a bifunctional PD1\/CTLA4 dual blocker, in patients with advanced solid tumors","volume":"16","author":"Zhao","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02067","article-title":"Dual PD-1 and CTLA-4 checkpoint blockade using balstilimab and zalifrelimab combination as second-line treatment for advanced cervical cancer: an open-label phase II study","volume":"40","author":"O'Malley","year":"2022","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005325","article-title":"Blocking soluble TNF\u03b1 sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression","volume":"11","author":"Bruni","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202206873","article-title":"Sustained intratumoral administration of agonist CD40 antibody overcomes immunosuppressive tumor microenvironment in pancreatic cancer","volume":"10","author":"Liu","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13045-022-01363-8","article-title":"Combination of oral STING agonist MSA-2 and anti-TGF-\u03b2\/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors","volume":"15","author":"Yi","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1065793","article-title":"Nanotechnology in cervical cancer immunotherapy: Therapeutic vaccines and adoptive cell therapy","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1042\/ebc20220241","article-title":"DNA sensing in cancer: Pro-tumour and anti-tumour functions of cGAS-STING signalling","volume":"67","author":"Wheeler","year":"2023","journal-title":"Essays Biochem"},{"key":"B29","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13045-021-01155-6","article-title":"Combine and conquer: manganese synergizing anti-TGF-\u03b2\/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers","volume":"14","author":"Yi","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20210108","article-title":"Anti-tumor immunity in mismatch repair-deficient colorectal cancers requires type I IFN-driven CCL5 and CXCL10","volume":"218","author":"Mowat","year":"2021","journal-title":"J Exp Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00005-017-0481-7","article-title":"STING signaling in cancer cells: important or not","volume":"66","author":"Sokolowska","year":"2018","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003960","article-title":"Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy","volume":"10","author":"Jiang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-020-03967-5","article-title":"Activation of STING inhibits cervical cancer tumor growth through enhancing the anti-tumor immune response","volume":"476","author":"Shi","year":"2021","journal-title":"Mol Cell Biochem"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba6098","article-title":"An orally available non-nucleotide STING agonist with antitumor activity","volume":"369","author":"Pan","year":"2020","journal-title":"Science"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.715077","article-title":"Identifying molecular changes in early cervical cancer samples of patients that developed metastasis","volume":"11","author":"de Geus","year":"2021","journal-title":"Front Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s11357-023-00742-4","article-title":"Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer","volume":"45","author":"Gy\u0151rffy","year":"2023","journal-title":"Geroscience"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.687975","article-title":"IOBR: multi-omics immuno-oncology biological research to decode tumor microenvironment and signatures","volume":"12","author":"Zeng","year":"2021","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.36","article-title":"Sangerbox: A comprehensive, interaction-friendly clinical bioinformatics analysis platform","volume":"1","author":"Shen","year":"2022","journal-title":"iMeta"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1097\/igc.0000000000000528","article-title":"Interleukin-28B plays a therapeutic role on mouse U14 cervical cancer cells by down-regulating CD4+CD25+FoxP3+Regulatory T cells in vivo","volume":"25","author":"Chen","year":"2015","journal-title":"Int J Gynecol Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003667","article-title":"Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer","volume":"10","author":"Wang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-18-1020","article-title":"Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer","volume":"9","author":"Sen","year":"2019","journal-title":"Cancer Discovery"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.immuni.2021.04.019","article-title":"The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake","volume":"54","author":"de Mingo Pulido","year":"2021","journal-title":"Immunity"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1097\/igc.0000000000001009","article-title":"Cervical adenocarcinoma has a poorer prognosis and a higher propensity for distant recurrence than squamous cell carcinoma","volume":"27","author":"Jung","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28857","article-title":"Diverse intratumoral heterogeneity and immune microenvironment of two HPV-related cervical cancer types revealed by single-cell RNA sequencing","volume":"95","author":"Li","year":"2023","journal-title":"J Med Virol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0235-4","article-title":"CD8(+) T cell states in human cancer: insights from single-cell analysis","volume":"20","author":"van der Leun","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.immuni.2022.12.008","article-title":"Microenvironment-driven metabolic adaptations guiding CD8(+) T cell anti-tumor immunity","volume":"56","author":"Park","year":"2023","journal-title":"Immunity"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.583084","article-title":"Tumor-associated macrophages in tumor immunity","volume":"11","author":"Pan","year":"2020","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1172\/jci137110","article-title":"Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma","volume":"130","author":"Loeuillard","year":"2020","journal-title":"J Clin Invest"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat Rev Drug Discovery"},{"key":"B52","doi-asserted-by":"publisher","first-page":"6101","DOI":"10.1016\/j.cell.2021.11.007","article-title":"Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses","volume":"184","author":"Cui","year":"2021","journal-title":"Cell"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.cmet.2023.07.001","article-title":"Tumor aerobic glycolysis confers immune evasion through modulating sensitivity to T cell-mediated bystander killing via TNF-\u03b1","volume":"35","author":"Wu","year":"2023","journal-title":"Cell Metab"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111874","article-title":"CD4(+) T cells drive an inflammatory, TNF-\u03b1\/IFN-rich tumor microenvironment responsive to chemotherapy","volume":"41","author":"Tilsed","year":"2022","journal-title":"Cell Rep"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aar3451","article-title":"Tumor immune evasion arises through loss of TNF sensitivity","volume":"3","author":"Kearney","year":"2018","journal-title":"Sci Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1342647\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:26:39Z","timestamp":1710375999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1342647\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,14]]},"references-count":55,"alternative-id":["10.3389\/fimmu.2024.1342647"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1342647","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,14]]},"article-number":"1342647"}}